| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Chronic myeloid leukemia in the imatinib era
|
Druker, Brian J.
|
|
2003
|
40 |
S2 |
p. 1-3
3 p.
|
artikel
|
| 2 |
Clinical decisions for chronic myeloid leukemia in the imatinib era
|
Goldman, John M.
|
|
2003
|
40 |
S2 |
p. 98-103
6 p.
|
artikel
|
| 3 |
Comments on the Hammersmith policy
|
Cortes, Jorge
|
|
2003
|
40 |
S2 |
p. 105-106
2 p.
|
artikel
|
| 4 |
Comments on the Hammersmith policy
|
Daley, George Q.
|
|
2003
|
40 |
S2 |
p. 106-
1 p.
|
artikel
|
| 5 |
Comments on the Hammersmith policy
|
Baccarani, Michele
|
|
2003
|
40 |
S2 |
p. 104-
1 p.
|
artikel
|
| 6 |
Comments on the Hammersmith policy
|
Guilhot, François
|
|
2003
|
40 |
S2 |
p. 108-109
2 p.
|
artikel
|
| 7 |
Comments on the Hammersmith policy
|
Hughes, Tim
|
|
2003
|
40 |
S2 |
p. 111-112
2 p.
|
artikel
|
| 8 |
Comments on the Hammersmith policy
|
Hochhaus, Andreas
|
|
2003
|
40 |
S2 |
p. 109-110
2 p.
|
artikel
|
| 9 |
Comments on the Hammersmith policy
|
Mahon, Francois-Xavier
|
|
2003
|
40 |
S2 |
p. 112-113
2 p.
|
artikel
|
| 10 |
Comments on the Hammersmith policy
|
Druker, Brian J.
|
|
2003
|
40 |
S2 |
p. 107-108
2 p.
|
artikel
|
| 11 |
Cytogenetic and molecular mechanisms of resistance to imatinib
|
Hochhaus, Andreas
|
|
2003
|
40 |
S2 |
p. 69-79
11 p.
|
artikel
|
| 12 |
Cytogenetic studies in patients on imatinib
|
Deininger, Michael W.N.
|
|
2003
|
40 |
S2 |
p. 50-55
6 p.
|
artikel
|
| 13 |
Imatinib: A targeted clinical drug development
|
Capdeville, Renaud
|
|
2003
|
40 |
S2 |
p. 15-20
6 p.
|
artikel
|
| 14 |
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials
|
Guilhot, François
|
|
2003
|
40 |
S2 |
p. 92-97
6 p.
|
artikel
|
| 15 |
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia
|
O'Brien, Stephen G.
|
|
2003
|
40 |
S2 |
p. 26-30
5 p.
|
artikel
|
| 16 |
Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studies
|
Tipping, Alex J.
|
|
2003
|
40 |
S2 |
p. 83-91
9 p.
|
artikel
|
| 17 |
Imatinib treatment: Specific issues related to safety, fertility, and pregnancy
|
Hensley, Martee L.
|
|
2003
|
40 |
S2 |
p. 21-25
5 p.
|
artikel
|
| 18 |
Molecular mechanisms of transformation by the BCR-ABL oncogene
|
Sattlermc, Martin
|
|
2003
|
40 |
S2 |
p. 4-10
7 p.
|
artikel
|
| 19 |
Molecular monitoring of chronic myeloid leukemia
|
Hughes, Tim
|
|
2003
|
40 |
S2 |
p. 62-68
7 p.
|
artikel
|
| 20 |
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment
|
Roche-Lestienne, Catherine
|
|
2003
|
40 |
S2 |
p. 80-82
3 p.
|
artikel
|
| 21 |
Prediction of response to imatinib by cDNA microarray analysis
|
Ohno, Ryuzo
|
|
2003
|
40 |
S2 |
p. 42-49
8 p.
|
artikel
|
| 22 |
Quality of life on imatinib
|
Hahn, Elizabeth A.
|
|
2003
|
40 |
S2 |
p. 31-36
6 p.
|
artikel
|
| 23 |
The cytogenetic response as a surrogate marker of survival
|
Rosti, Gianantonio
|
|
2003
|
40 |
S2 |
p. 56-61
6 p.
|
artikel
|
| 24 |
Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors
|
Daley, George Q.
|
|
2003
|
40 |
S2 |
p. 11-14
4 p.
|
artikel
|
| 25 |
Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy
|
Cilloni, Daniela
|
|
2003
|
40 |
S2 |
p. 37-41
5 p.
|
artikel
|
Tijdschrift beschrijving